The Company is a leading pure-play specialty oncology pharmacy with two primary units: (i) Drug Distribution and Related Services and (ii) Payor Services.
The two primary owners of the Company were looking to find a partner that could provide a full or partial liquidity event to help them reduce personal financial risk concentration. Trestle was asked to explore all strategic options that might help the owners achieve this goal.
After a thorough process that involved conversations with a large number of potential financial and strategic partners, the owners sold a majority stake in the Company to a private equity group. The agreement also included a provision for additional staged equity acquisitions by the private equity partner that provided additional liquidity events to the owners. The Company was ultimately sold to a large strategic acquiror, which provided a final liquidity event to the owners as they divested their residual equity ownership.